Harvard Bioscience, Inc. Share Price

Equities

HBIO

US4169061052

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
3.62 USD +1.69% Intraday chart for Harvard Bioscience, Inc. -2.16% -32.34%
Sales 2024 * 114M 9.13B Sales 2025 * 126M 10.05B Capitalization 157M 12.58B
Net income 2024 * - 0 Net income 2025 * 3M 240M EV / Sales 2024 * 1.38 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.25 x
P/E ratio 2024 *
-724 x
P/E ratio 2025 *
48.3 x
Employees 404
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.72%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.69%
1 week-2.16%
Current month-14.62%
1 month-9.95%
3 months-20.61%
6 months-16.40%
Current year-32.34%
More quotes
1 week
3.44
Extreme 3.44
3.84
1 month
3.44
Extreme 3.44
4.70
Current year
3.44
Extreme 3.44
5.44
1 year
3.44
Extreme 3.44
6.29
3 years
1.98
Extreme 1.98
8.75
5 years
1.39
Extreme 1.39
8.75
10 years
1.39
Extreme 1.39
8.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 27/04/15
Director of Finance/CFO 52 30/04/22
Chief Operating Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 65 27/04/15
Director/Board Member 56 02/09/19
Director/Board Member 58 05/11/14
More insiders
Date Price Change Volume
26/04/24 3.62 +1.69% 55,311
25/04/24 3.56 -3.52% 65,306
24/04/24 3.69 -0.81% 63,556
23/04/24 3.72 +0.54% 92,096
22/04/24 3.7 0.00% 90,516

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.62 USD
Average target price
7 USD
Spread / Average Target
+93.37%
Consensus